Market News


ANTIBIOTICE S.A. - ATB

Tender result in the United Kingdom of Great Britain

Release Date: 12/2/2021 8:27:39 AM

IRIS Code: 2C47E

 

 

CURRENT REPORT

                                                                                          

Reporting date: 01.12.2021

Name of the issuing entity: Antibiotice SA

Registered office: Iasi, str. Valea Lupului nr.1, cod postal 707410, 

http://www.antibiotice.ro

E-mail: relatiicuinvestitorii@antibiotice.ro

Phone/fax number: +40232 209000 / 0372 065 633

Sole Registration Code with the Trade Register Office: RO1973096

Order number in the Trade Register Office: J22/285/1991

Subscribed and paid share capital: 67.133.804 lei

Regulated market on which the issued securities are traded: Bucharest Stock Exchange

Number of shares: 671.338.040

Number of votes: 671.338.040

The main characteristics of the securities issued by the trading company: registered shares, nominal value: 0.10 lei

 

Important event to be reported:

 

 

Antibiotice wins tender worth 11 million euros in the UK


Antibiotice Iasi won the tender held by the UK Department of Health and Social Care for a number of 5 anti-infective products for injection.
 

Antibiotice won the tender launched by the UK authorities for five injectable anti-infectives (for hospital use), which are used in the treatment of Covid-19 associated bacterial superinfections as well.   

 

We are glad that today, on December 1, Antibiotice – a Romanian brand with 65 years of history – can make this achievement known. It is a further proof that high level of performance can be attained in our country as well, that Romania has a future!

The value of the recently concluded contract amounts to EUR 11 million, which not only allows the future consolidation of the business, but also reconfirms our status of medicinal product manufacturer accepted by one of the largest regulated markets in Western Europe”, said Ioan Nani, the CEO of Antibiotice.  

The contract will run for a period of 2 years, and the first deliveries will be made starting January 2022, without jeopardizing the supply of all hospitals in Romania with beta-lactam medicinal products for injection.

Entering the UK market is part of the territorial expansion strategy of Antibiotice, which is included in the company’s long-term Strategic Organization and Development Plan. Moreover, aiming at enhancing its portfolio in the coming years by adding products adapted to the today’s therapeutics, Antibiotice carries out different projects in Brazil, Australia and Northern Europe countries (Finland, Sweden, Norway, Denmark). Such projects will increase the presence of the company in these markets and generate significant sales.

In recent years, Antibiotice has won important tenders for anti-infective medicines in the US, Western Europe, Southeast Asia, as well as the tender launched by the European Committee in 2020, intended to ensure the appropriate supply with beta-lactam antibiotics of the member states during the pandemics. This represents a tru acknowledgement of the quality of the medicinal products manufactured by Antibiotice at Iasi, in Romania.

 

 

 

 

General Director,

Ec. Ioan NANI

 

 

 



 Print

Information provided by IRIS, the news platform of the Bucharest Stock Exchange.

______________________

Bucharest Stock Exchange ("BVB") is not responsible for the content of this News item. Issuers whose financial instruments are traded on markets operated by BVB are required to report in accordance with current legal and regulatory provisions. BVB publishes these Reports as market administrator, appointed by ASF. When, for investors’ information, Reports are published, either signed by different persons, or with conflicting information, legal liability lies fully with the signatories. BVB disclaims any obligation or responsibility towards issuers or third parties, regarding the reality, completeness and accuracy of information provided by them and distributed by BVB. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.


©2016 Bucharest Stock Exchange. All rights reserved